Even though biologics including anti-IL17A, anti-IL-12p40 or IL-23p40, and anti-IL-23p19 antibodies are highly effective in reducing the Psoriasis Area Severity Index (PASI) score, skin lesions can reoccur during the treatment and after discontinued therapy, highlighting a gap in the understanding of the immune dysregulation occurring during psoriasis [4]. This evidence concerns the gene IL17A and psoriasis.